Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV001379105 | SCV001576839 | pathogenic | Maple syrup urine disease | 2021-03-29 | criteria provided, single submitter | clinical testing | This sequence change affects an acceptor splice site in intron 1 of the DBT gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in DBT are known to be pathogenic (PMID: 16579849, 16786533). This variant is not present in population databases (ExAC no frequency). This variant has been observed in individual(s) with maple syrup urine disease (Invitae). In at least one individual the data is consistent with the variant being in trans (on the opposite chromosome) from a pathogenic variant. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site, but this prediction has not been confirmed by published transcriptional studies. For these reasons, this variant has been classified as Pathogenic. |
| Baylor Genetics | RCV001379105 | SCV004190869 | likely pathogenic | Maple syrup urine disease | 2023-03-16 | criteria provided, single submitter | clinical testing |